[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473460":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":39,"locations":46,"responsibleParty":64,"collaborators":18,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":18,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":18,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":18,"overallStatus":48,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Douglas Mental Health University Institute","OTHER",[8,14,19,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Psychosis patients with cannabis use (Abstinent)","EXPERIMENTAL","Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days",[13],"Behavioral: Contingency management",{"label":15,"type":16,"description":17,"interventionNames":18},"Psychosis patients with cannabis use (Non-abstinent)","NO_INTERVENTION","Psychosis Patients with cannabis use who will continue to use cannabis as usual",null,{"label":20,"type":10,"description":21,"interventionNames":22},"Non-Psychiatric controls with cannabis use (Abstinent)","Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days",[13],{"label":24,"type":16,"description":25,"interventionNames":18},"Non-Psychiatric controls with cannabis use (Non-abstinent)","Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual",{"label":27,"type":16,"description":28,"interventionNames":18},"Non-Psychiatric Controls without cannabis use","Non-Psychiatric controls without cannabis use",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":18},"BEHAVIORAL","Contingency management","Contingency management will be used to encourage abstinence",[20,9],[36],{"name":37,"affiliation":5,"role":38},"Rachel Rabin, Ph. D.","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Charlene Osei-Afrifa","CONTACT","(514) 761-6131","3348","aimh.research@gmail.com",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Montreal","Quebec","H4H 1R3","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-73.58781,45.50884,{"lat":58,"lon":57},[61,63],{"name":62,"role":42,"phone":43,"phoneExt":44,"email":45},"Research Coordinator",{"name":37,"role":38,"phone":18,"phoneExt":18,"email":18},{"type":38,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Rachel Rabin","Assistant Professor","100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460",false,"NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication",true,"ALL","16 Years","80 Years",{"count":79,"type":80},134,"ESTIMATED","INTERVENTIONAL",[83],"NA","Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[86,87,88,89,90,91,92,93],"Psychotic Disorders","Cannabis Use Disorder","Cannabis Dependence","Cannabis Use","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","Neuroimaging","2026-05-19",{"date":96,"type":97},"2026-05-22","ACTUAL",{"date":99,"type":97},"2022-04-21",{"date":101,"type":80},"2027-05",{"name":5,"class":6},1]